Business Description
Spyre Therapeutics Inc
NAICS : 325412
SIC : 2834
Description
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. A range of pharmaceutical options to address IBD exists, including anti-inflammatory drugs, immunosuppressants, and biologics.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 111.9 | |||||
| Equity-to-Asset | 0.31 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | -0.03 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -1 | |||||
| Beneish M-Score | -4.75 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 21.1 | |||||
| 3-Year EPS without NRI Growth Rate | 18.6 | |||||
| 3-Year FCF Growth Rate | 27.2 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 55.08 | |||||
| 9-Day RSI | 54.72 | |||||
| 14-Day RSI | 52.96 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 11.38 | |||||
| Quick Ratio | 11.38 | |||||
| Cash Ratio | 11.32 | |||||
| Days Sales Outstanding | 187.01 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -165.9 | |||||
| Shareholder Yield % | 0.02 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -22897.09 | |||||
| Net Margin % | -52939.68 | |||||
| FCF Margin % | -16141.26 | |||||
| ROA % | -136.65 | |||||
| ROIC % | -343.95 | |||||
| ROC (Joel Greenblatt) % | -3018.63 | |||||
| ROCE % | -81.36 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 207.67 | |||||
| EV-to-EBIT | -8.63 | |||||
| EV-to-EBITDA | -8.65 | |||||
| EV-to-Revenue | 1975.2 | |||||
| EV-to-FCF | -12.2 | |||||
| Price-to-Net-Cash | 8.67 | |||||
| Earnings Yield (Greenblatt) % | -11.6 | |||||
| FCF Yield % | -7.33 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Spyre Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.635 | ||
| EPS (TTM) (€) | -63.843 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 52.96 | ||
| 14-Day ATR (€) | 1.245408 | ||
| 20-Day SMA (€) | 32.0075 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (€) | 29.85 - 40.9 | ||
| Shares Outstanding (Mil) | 40.28 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Spyre Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Spyre Therapeutics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Spyre Therapeutics Inc Frequently Asked Questions
What is Spyre Therapeutics Inc(FRA:3920)'s stock price today?
The current price of FRA:3920 is €33.80. The 52 week high of FRA:3920 is €40.90 and 52 week low is €29.85.
When is next earnings date of Spyre Therapeutics Inc(FRA:3920)?
The next earnings date of Spyre Therapeutics Inc(FRA:3920) is 2024-08-09 Est..
Does Spyre Therapeutics Inc(FRA:3920) pay dividends? If so, how much?
Spyre Therapeutics Inc(FRA:3920) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers